1.
Economic evaluation of pooled solvent/detergent treated plasma versus single donor fresh-frozen plasma in patients receiving plasma transfusions in the United States
Huisman EL, de Silva SU, de Peuter MA
Transfusion & Apheresis Science. 2014;51((1):):17-24.
Abstract
This study assessed the cost-effectiveness of Octaplas versus fresh frozen plasma (FFP) in patients receiving plasma transfusions in the United States (US). Acute and long-term complications of plasma transfusions were modelled in a decision tree followed by a Markov model, using a healthcare payer perspective. Over a lifetime time horizon, patients receiving Octaplas accumulate slightly more life years (0.00613 [95% uncertainty interval (95%UI): 0.00166-0.01561]) and quality-adjusted life years (QALY) (0.023 [95%UI: 0.012-0.044]) at lower cost compared with those treated with FFP. Octaplas demonstrated to be the dominant treatment option over FFP (95%UI: Dominant-US$ 15,764/QALY). Copyright 2014 Elsevier Ltd. All rights reserved.
2.
Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada
Huisman EL, van Eerd MC, Ouwens JN, de Peuter MA
Transfusion & Apheresis Science. 2014;51((1):):25-34.
Abstract
The objectives of this study were to evaluate the cost-effectiveness and budget impact of octaplasLG compared with fresh-frozen plasma (FFP) in all patients receiving a transfusion in Canada. A decision analytic framework was used to model acute and long-term complications that could follow plasma transfusion. Over a life time horizon, the cost with octaplasLG were CA$612.91, which is CA$303.14 less than those with FFP. OctaplasLG resulted in 0.021 quality adjusted life years (QALYs) gained in comparison with FFP. Because of higher efficacy and lower costs, octaplasLG is expected to be the dominant treatment option over FFP in Canada. Copyright 2013 Elsevier Ltd. All rights reserved.